Home › Funds › PAYDEN & RYGEL › GILD

PAYDEN & RYGEL position in GILD

GILEAD SCIENCES INC · Health Care

PAYDEN & RYGEL reported holding 126,360 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$18.8M, representing 1.47% of its reported portfolio and ranking #21 among its reported holdings. PAYDEN & RYGEL has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)126.36K sh
Reported value held$18.83M
Portfolio Weight1.47%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How PAYDEN & RYGEL's GILD position evolved

PAYDEN & RYGEL first disclosed a stake in GILD in Q3 2023 at 2,680 shares (US$201K). The position peaked in Q3 2026 at 126,360 shares, worth US$18.8M. Across 13 filings, PAYDEN & RYGEL increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 126,360 shares valued at US$18.8M. Notable position changes include a 93% trim in Q2 2024 (shares rose 22% over the following quarter), a 37889% increase in Q2 2025 (shares were roughly flat over the following quarter), a 39% increase in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.68K $201.00K New
Q4 2023 2.68K $217.00K Hold
Q1 2024 2.68K $196.00K Hold
Q2 2024 180 $12.00K Reduce
Q3 2024 180 $15.00K Hold
Q4 2024 180 $17.00K Hold
Q1 2025 180 $20.00K Hold
Q2 2025 68.38K $7.58M Add
Q3 2025 91.28K $10.13M Add
Q4 2025 91.28K $11.20M Hold
Q1 2026 91.28K $12.72M Hold
Q2 2026 126.56K $15.99M Add
Q3 2026 126.36K $18.83M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has PAYDEN & RYGEL held GILD?

PAYDEN & RYGEL has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is PAYDEN & RYGEL's current position in GILD?

As of Q3 2026, PAYDEN & RYGEL holds 126.36K shares of GILD (GILEAD SCIENCES INC), valued at $18.83M, representing 1.47% of its reported portfolio and ranking #21.

Has PAYDEN & RYGEL been buying or selling GILD?

In the latest 13F filing (Q3 2026), PAYDEN & RYGEL held unchanged its position in GILD. The position peaked in Q3 2026 at 126.36K shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.